ASX shares that experts rate very positively could be exciting opportunities.

When some businesses have received numerous buy ratings from experts, they are worth a closer look.

Businesses with rapidly growing revenue could be particularly compelling.

Life360 Inc. (ASX: 360)

Life360 is best known as a tech business that provides an app for families to keep track of each other. It operates in numerous countries, including the US, the UK, ANZ and Canada.

It’s currently rated as a buy by 14 analysts, according to Commsec. It’s one of the most heavily backed ASX shares right now.

The company is growing strongly – in the second quarter of 2026, it revealed significant growth.

Revenue grew by 38% to $159 million, with monthly active users (MAU) rising 16% to 102.4 million and paying global circles growing by 27% to 3.2 million. US paying circles grew 25% to 2.3 million and international paying circles soared 34% to 0.4 million.

The ASX share has looked to monetise its non-paying circles through advertising. In the three months to June 2026, advertising revenue grew 315% to $22 million.

Life360’s profitability metrics are also expanding rapidly. Adjusted operating profit (EBITDA) grew 53% to $20.3 million and positive operating cash flow soared 79% to $23.8 million.

Given that Life360’s share price is down more than 60% over the past year (at the time of writing), it could be a very underrated business at this valuation amid worries about AI.

Pro Medicus Ltd (ASX: PME)

Pro Medicus is another ASX share that is strongly backed by analysts.

It is currently rated as a buy by nine analysts, according to Commsec.

Pro Medicus describes itself as a leading healthcare informatics company. It says it provides a full range of medical imaging software and services to hospitals, imaging centres and healthcare groups worldwide.

FY26 was another strong year for the company – revenue grew 22.9% to $261.7 million, underlying operating profit (EBIT) rose 24.4% to $196.1 million, and underlying net profit increased 24.1% to $144.7 million.

However, given how much of the ASX share’s revenue now comes from the US, foreign currency plays a sizeable role in the financials. If exchange rates hadn’t changed, underlying revenue would have grown 28.4% to $273.5 million, underlying EBIT would have risen 30.6% to $206 million and underlying NPAT would have risen 32.5% to $154.5 million.

Future earnings growth looks very positive, with the company signing 10 new contracts worth a minimum of A$407 million and renewing six (out of six) contracts worth A$141 million at higher transaction rates.

Perhaps most impressively of all, the EBIT margin improved by 90 basis points to 74.9% in FY26.

It’s not cheap, but the Pro Medicus share price has dropped around 50% in the past year, making the ASX share much more attractive.

The post 2 ASX shares highly recommended to buy: Experts appeared first on The Motley Fool Australia.

More reading

• Tech shares shine while ASX 200 plunges to 4-month low
• Why I just invested $1,500 into this top ASX growth share
• Here are the top 10 ASX 200 shares today
• Here are the top 10 ASX 200 shares today
• Brokers tip up to 67% for these 3 ASX shares

Motley Fool contributor Tristan Harrison has positions in Pro Medicus. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Life360. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has positions in and has recommended Life360. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

On Tuesday, the S&P/ASX 200 Index (ASX: XJO) continued its positive run with a solid gain. The benchmark index rose 0.55% to 8,735.7 points

Will the market be able to build on this on Wednesday? Here are five things to watch:

ASX 200 to edge lower

The Australian share market is expected to edge lower on Wednesday despite a strong session on Wall Street. According to the latest SPI futures, the ASX 200 is expected to open the day 1 point lower. In the United States, the Dow Jones rose 0.5%, the S&P 500 climbed 0.6%, and the Nasdaq pushed 0.45% higher.

Oil prices rise

ASX 200 energy shares Beach Energy Ltd (ASX: BPT) and Santos Ltd (ASX: STO) could have a decent session on Wednesday after oil prices rose overnight. According to Bloomberg, the WTI crude oil price is up 0.4% to US$89.80 a barrel and the Brent crude oil price is up 0.65% to US$100.96 a barrel. Traders were bidding oil higher in response to supply risks.

Buy Deterra shares

The team at Morgans thinks Deterra Royalties Ltd (ASX: DRR) shares could be good value. The broker has retained its buy rating on the mining royalties company’s shares with a trimmed price target of $4.75. It said: “Deterra has announced the acquisition of a 1.75% NSR royalty on ~84% of Ivanhoe Electric’s Santa Cruz copper project for US$74.15m cash. As part of the deal reduced to 1.68% NSR for first 6 years of production, and 1.57% thereafter, with a current 24-year mine life. >We value the Santa Cruz royalty at risked A$110m, or A$0.21/share, and expect it to add A$17-21mpa to EBITDA by FY30F (~7% earnings accretive). A formidable inflation hedge with upside leverage to metal prices, we maintain a BUY rating with a A$4.75 Target Price (was A$4.85).”

Gold price rises

ASX 200 gold shares Westgold Resources Ltd (ASX: WGX) and Northern Star Resources Ltd (ASX: NST) could have a good session on Wednesday after the gold price pushed higher. According to CNBC, the gold futures price is up 0.8% to US$4,191.5 an ounce. This was driven by a weaker US dollar and softening Treasury yields.

Dicker Data shares on watch

Dicker Data Ltd (ASX: DDR) shares will be on watch on Wednesday if they return from their trading halt. The computer hardware and software distributor requested a trading halt as it prepared to announce a binding agreement to acquire 100% of Sektor Group for around A$111.8 million. Executive Chair and Managing Director, Fiona Brown, said: “Sektor expands our reach into attractive adjacent categories including point-of-sale and enterprise mobility as well as further strengthening our physical security and cybersecurity offering. Importantly, Sektor also provides Dicker Data with an established operational footprint in Thailand and Malaysia, accelerating our regional expansion strategy.”

The post 5 things to watch on the ASX 200 on Wednesday appeared first on The Motley Fool Australia.

More reading

• Here are the top 10 ASX 200 shares today
• 5 things to watch on the ASX 200 on Tuesday
• This ASX health technology company could more than double in value: Broker
• Buy, hold, sell: Megaport, Northern Star, Woolworths shares
• 5 things to watch on the ASX 200 on Monday

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has positions in and has recommended Dicker Data. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Healius vs Australian Clinical Labs shares

If you’re considering a slice of Australia’s diagnostic healthcare sector, you might be torn between Healius Ltd (ASX: HLS) and Australian Clinical Labs Ltd (ASX: ACL) shares. Both companies are big names in pathology, with nationwide reach and established reputations. But their fundamentals, dividends, and recent share price momentum tell very different stories. Let’s dive into what really sets these two healthcare stocks apart.

The case for Healius

Healius is one of Australia’s largest pathology service providers, operating under well-known brands like Laverty, Dorevitch, and QML Pathology. Healius ran around 2,000 collection sites and close to 100 labs across the country. In May 2025, Healius sold its Lumus Imaging business and now focuses on pathology and its bioanalytical laboratory arm, Agilex Biolabs.

Looking at current fundamentals, three points really stand out:

• The share price has been hammered this year, with a -52.5% year-to-date return.
• Healius’s P/E ratio is 55.56, with an earnings per share of -0.563. (Note: Healius’s reported P/E ratio may be based on a different earnings measure than the EPS figure shown, which is why they may appear inconsistent.)
• Dividend yield is currently 0.00%. Despite a long history of fully franked payouts, the last special dividend was paid in May 2025, and before that, ordinary dividends dried up after 2022.

So while Healius is a large, established player with an extensive network, it’s struggling for profitability and income at the moment.

The case for Australian Clinical Labs

Australian Clinical Labs is another leading pathology player, with a strong footprint across nearly all states and territories (excluding Tasmania). The company operates more than 75 laboratories and 1,300 collection centres, handling over 12 million episodes a year. ACL is also a significant provider to both private and public hospitals, and increasingly active in specialised screenings and commercial testing.

Here are a few of the most notable fundamentals right now:

• Year-to-date return is a healthy 8.4%—a far cry from Healius’s collapse.
• The P/E ratio is 23.11, backed by positive earnings per share of 0.141.
• Dividend yield is 4.56%, with 100% franking. ACL has delivered regular, fully franked dividends; the latest was 9.25 cents per share in September 2026.

Overall, ACL is profitable, growing, and paying out a solid stream of income.

Valuation comparison

Here’s how the two companies stack up on key numbers:

Metric	Healius	Australian Clinical Labs
Market Cap	$305.00 million	$514.79 million
P/E Ratio	55.56 (Note: P/E may not be based on the EPS shown, which is negative)	23.11
Earnings per share (EPS)	-0.563	0.141
Dividend Yield	0.00%	4.56%
Franking	100%	100%
YTD Return	-52.5%	8.4%

While both companies offer fully franked dividends, only ACL is currently paying and yielding above 4%. Healius has lost significant ground—both in share price and earnings.

Recent share price momentum

Comparing recent share price performance up to 1 October 2026:

• Healius closed at $0.42 on 1 October 2026, down 2.3% on the day and showing steep declines so far in 2026. Year to date, Healius is down 52.5%.
• Australian Clinical Labs closed at $2.76 on 1 October 2026, falling 3.2% that day, but overall in positive territory for 2026 with an 8.4% gain year to date.

Both shares dipped on the last trading day, but their trajectories are worlds apart this year. Healius has been in steep decline; ACL has outperformed and delivered positive momentum.

Which is the better buy?

If I had to choose between Healius and Australian Clinical Labs today, my pick would be clear: Australian Clinical Labs. The company is profitable, offers a solid fully franked dividend yield, and has delivered meaningful share price growth this year. Meanwhile, Healius is battling negative earnings, has halted regular dividends, and has seen its market cap and share price tumble by more than half in 2026. ACL’s lower P/E ratio (compared to Healius) also suggests investors aren’t paying as much for each dollar of earnings, at least within the context of these two healthcare stocks. While both serve a vital role in Australian pathology and may benefit from long-term healthcare trends, only ACL currently pairs business quality with real income and positive momentum. That’s where I’d be leaning with my investment dollars today.

The post Healius vs Australian Clinical Labs: Which ASX pathology share wins? appeared first on The Motley Fool Australia.

More reading

• 6 ASX shares upgraded by experts amid a weak market 
• Buy, hold, sell: Netwealth, Tabcorp, Healius shares

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial draft. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.